Practical Prescribing and Medication Management of PARP Inhibitor Therapy for Ovarian Cancer

Practical Prescribing and Medication Management of PARP Inhibitor Therapy for Ovarian Cancer

Live Webinar
Date Time
Wednesday, May 23, 2018 1:15pm to 2:15pm ET Register
Friday, May 25, 2018 1:15pm to 2:15pm ET Register
Wednesday, May 30, 2018 12:15pm to 1:15pm ET Register
Friday, June 15, 2018 3:15pm to 4:15pm ET Register
Wednesday, June 27, 2018 11:15am to 12:15pm ET Register
Faculty

Program Chair
Robert L. Coleman, MD

Professor of Gynecologic Oncology
Vice Chair of Clinical Research
University of Texas MD Anderson Cancer Center
Houston, Texas

Panelists
Laura Alwan, PharmD, BCOP
Clinical Pharmacist, Hematology/Oncology
University of Washington Medical Center/
Seattle Cancer Care Alliance
Seattle, Washington

Judith A. Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP
Associate Professor
Director
Women’s Health Integrative Medicine Research Program
McGovern Medical School
The University of Texas Health Science Center at Houston
Houston, Texas

Casey Williams, PharmD, BCOP, FHOPA
Director
Avera Center for Precision Oncology
Department of Molecular and Experimental Medicine
Avera Cancer Institute
Sioux Falls, South Dakota

Intended Learners

This activity is designed for health-system pharmacists including specialty pharmacists, clinical pharmacists, oncology pharmacists, and other pharmacists involved in the management of patients with ovarian cancer.

Learning Objectives

At the completion of this activity, the participant will be better able to:

  • Differentiate between available PARP inhibitors based on unique pharmacologic and clinical profiles
  • Elaborate on findings from pivotal clinical trials of both currently available and emerging PARP inhibitors
  • Develop plans for effective patient education materials on dosing PARP inhibitors and ameliorating adverse effects
  • Formulate a plan for counseling other members of the cancer care team, as well as patients, about using PARP inhibitors as maintenance therapy
Activity Overview

In order to be eligible for documentation of credit, participants must complete the pre-test, attend the full webinar, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, Imedex will not be able to report your credit to CPE Monitor after this 60 day period.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Provider


This activity is provided by Imedex®, LLC.

 

CPE

Imedex®, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity ( UAN: 0408-0000-18-005-H01-P) has been approved for a maximum of 1 contact hour (0.1 CEU).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by Imedex may contact the Senior Director, Accreditation and Compliance, in writing at 11675 Rainwater Dr # 600, Alpharetta, GA 30009. Imedex will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to Imedex's Compliance Officer can be made for a second level of review.

Planning Committee

The planning committee comprises Laura Alwan, PharmD, BCOP; Robert L. Coleman, MD; Judith A. Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP; Casey Williams, PharmD, BCOP, FHOPA

Monalisa Singh, MD, PhD, Susan Yarbrough, Imedex; Kristin Ciszeski, Molly Duda, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Alwan: Disclosures will be provided prior to the activity

Dr. Coleman: Disclosures will be provided prior to the activity

Dr. Smith: Disclosures will be provided prior to the activity

Dr. Williams: Disclosures will be provided prior to the activity

Ms. Ciszeki, Ms. Duda, Ms. Singh, and Ms. Yarbrough  have disclosed no relevant financial relationships with any commercial interests.

Privacy Policy

NACCME and Imedex protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex  maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by Imedex, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Imedex. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or Imedex . Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

Supported by an educational grant from Clovis Oncology, Inc.